Targeting EGFR signalling pathway in triple negative breast cancer
<p>Epidermal growth factor receptor (EGFR) is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic response...
| Huvudupphovsman: | |
|---|---|
| Övriga upphovsmän: | |
| Materialtyp: | Lärdomsprov |
| Språk: | English |
| Publicerad: |
2014
|
| Ämnen: |